Sally Wagner Partin
Advertisement
Sally Wagner Partin is a partner at Sidley Austin LLP across life sciences M&A and FDA regulatory practice.
Articles by Sally Wagner Partin
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
FDA Clears Trodelvy for First-Line Metastatic Triple-Negative Breast Cancer
2
The Rise of Direct-to-Patient Models in Pharma: Opportunities and Risks in Bypassing Traditional Distribution Channels
3
EMA’s CHMP Recommends Eli Lilly’s Jaypirca for Approval
4
Novartis Announces $105 Million Collaborative Agreement with Antares Therapeutics
5